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Abstract: Pancreatic adenocarcinoma is a common malignancy that remains refractory to 
available therapies. Gemcitabine has long been the standard, first-line agent in advanced disease. 
The epidermal growth factor receptor (EGFR) is a commonly expressed target in pancreatic 
cancer that is involved in tumor proliferation, metastasis, and induction of angiogenesis. The 
addition of the EGFR inhibitor erlotinib to gemcitabine has recently been demonstrated to 
provide a small, yet statistically significant, survival benefit in advanced disease. This has 
prompted further research into the applications of EGFR-targeted therapy in pancreatic cancer, 
albeit with disappointing results. Resistance to these therapies seems highly prevalent and has 
been implicated in their limited efficacy. The development of rash is associated with treatment 
efficacy and suggests that predictive factors may one day be identified to guide appropriate 
patient selection for these agents. Preclinical research has shown promise that resistance to 
EGFR-targeted therapies can be overcome through a variety of approaches. Application of this 
research in clinical trials may ultimately yield an unquestioned role for EGFR-targeted therapy 
in the management of this disease.
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Introduction
Adenocarcinoma of the pancreas remains a highly treatment-refractory malignancy. 
Although it is only the thirteenth most common cause of cancer worldwide, it is the 
eighth most common cause of cancer-related death.1 Gemcitabine remains the standard 
first-line cytotoxic agent for metastatic disease since demonstrating superiority 
over fluorouracil monotherapy.2 Median survival of gemcitabine-treated patients 
with advanced disease is 5 to 6 months. Recently, a small, statistically significant 
improvement in overall survival (OS) was demonstrated by the addition of EGFR-
targeted therapy to gemcitabine, bringing to question a new standard regimen.3 This 
finding has prompted continued exploration of the role of EGFR-targeted therapies in 
the management of pancreatic adenocarcinoma. The modest nature of the improvement 
resulting from erlotinib therapy, however, has also prompted efforts to understand the 
mechanisms of resistance to EGFR inhibition, which seem to be highly prevalent in 
this disease.
EGFR biology in pancreatic adenocarcinoma
The EGFR, also known as ErbB1, is a 170 kDa protein belonging to the four-member 
ErbB family of transmembrane tyrosine kinase growth factor receptors. Binding by Biologics: Targets & Therapy 2009:3 420
Faller and Burtness Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
a number of ligands induces conformational alterations in 
the single chain receptor, allowing dimerization or oligo-
merization with other EGFR molecules or other members of 
the ErbB family. Multimer formation leads to asymmetric 
autophosphorylation of a tyrosine residue on the intracellular 
portion of one of the molecules, allowing the receptor to 
recruit docking proteins and signal transduction molecules. 
The resulting cascades, involving the Ras/mitogen-activating 
protein (MAP) kinase pathway, the Phosphoinositide-3 
kinase (PI3K)/Akt pathway, Src family kinases, and signal 
transducers and activator of transcription (STAT) proteins, 
result in upregulation of mitogenic, antiapoptotic, angiogenic, 
and pro-invasive cellular mechanisms.4 Several routes to 
aberrant receptor activity in malignancy have been described, 
including receptor over-expression, mutation, ligand-
dependent receptor dimerization, and ligand-independent 
activation. As an example, activating mutations in the gene 
for the downstream regulating protein, KRAS, have been 
found to be highly prevalent in pancreatic cancer.5,6 Evidence 
from genetically engineered mouse models supports the role 
of these activating KRAS mutations in the pathogenesis of 
pancreatic cancer.7
EGFR is expressed in 30% to 89% of pancreatic cancers 
assayed by immunohistochemistry techniques.8,9 Its expression 
had been shown to correlate with worse outcome and more 
aggressive disease in small case series.10 A more recent review 
of pancreatic cancer cases at the Ohio State University pub-
lished in 2006, however, found conflicting data. In this series, 
EGFR was expressed in 69% of the 71 cases. Its expression did 
not correlate with tumor grade, size, lymphatic involvement, or 
survival. In fact, there was a nonstatistically significant trend 
for longer survival in the patients whose tumors expressed 
EGFR (median OS: 15.2 months vs 8.3 months).11
Exposure of pancreatic cancer cell lines to gemcitabine 
results in increased phosphorylation and thus activition 
of EGFR.12 This can be effectively blocked by tyrosine 
kinase inhibitors of EGFR, leading to tumor apoptosis.13,14 
In xenograft models of pancreatic cancer, the combination of 
gemcitabine and EGFR-targeted therapy significantly inhibits 
lymph node and liver metastasis and results in improved 
overall survival.13
A major partner of EGFR, HER-2 (ErbB2), has also been 
shown to be overexpressed in numerous human cancers and 
is associated with multiple drug resistance, higher meta-
static potential, and decreased patient survival.15 Aberrant 
HER-2 expression in pancreatic cancer has been reported 
in a number of studies, with a prevalence ranging from 7% 
to 58%.15 Expression of EGFR-related protein (ERRP), 
an effective pan-erbB inhibitor, has been found to correlate 
inversely with the degree of differentiation in pancreatic 
cancer. Likewise, low levels of ERRP are associated with 
poor clinical outcome.16
EGFR inhibitors
Small molecular inhibitors of EGFR, such as erlotinib and 
gefitinib, act by competing with adenosine-5′-triphosphate 
(ATP) for the intracellular tyrosine kinase domain of the 
receptor. They thereby inhibit EGFR autophosphorylation, 
and thus downstream signaling.17 These agents are 
administered orally and have dose-limiting toxicities of a 
characteristic rash, diarrhea, and an interstitial lung disease-
like syndrome, possibly below the most effective dose for 
some agents. Significant pharmacogenomic variability in 
absorption and metabolism has been described.18 Several 
small-molecule EGFR tyrosine kinase inhibitors (TKI) 
can block multiple growth factor receptor tyrosine kinases, 
including other members of the ErbB family, or the vascular 
endothelial growth factor receptor (VEGFR). Lapatinib is 
one such molecule that reversibly inhibits both Her2 (ErbB2) 
and, less potently, EGFR. Small-molecule TKIs have the 
theoretical advantage of inhibiting ligand-independent 
activity of EGFR. Erlotinib and gefitinib have been asso-
ciated with greater efficacy in nonsmall cell lung cancers 
(NSCLC) bearing activating mutations in the EGFR tyrosine 
kinase domain.19
Anti-EGFR monoclonal antibodies have been developed 
that competitively bind the extracellular ligand-binding 
region of the receptor in its inactivated position. Once bound, 
they prevent ligand binding and receptor dimerization. 
These agents therefore block endogenous ligand activation 
of EGFR in a highly specific manner, but may fail to inhibit 
ligand-independent activity. Two such examples include 
cetuximab, a human–murine IgG1 chimeric antibody, and 
panitumumab, a fully humanized IgG2 antibody. Both agents 
are well tolerated with predominant toxicities including rash, 
diarrhea, and hypomagnesemia. Serious hypersensitivity 
reactions, associated with pre-existing immunoglobulin 
(Ig)E antibodies against galactose-alpha-1,3-galactose, 
may occur during infusion of cetuximab;20 hypersensitivity 
reactions occur far less commonly with panitumumab, and 
the mechanism of these is not identified.21
EGFR tyrosine kinase inhibitors 
in advanced pancreatic cancer
The National Cancer Institute of Canada Clinical Trials 
Group (NCIC CTG) performed the only trial to demonstrate Biologics: Targets & Therapy 2009:3 421
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OS benefit from the addition of EGFR targeted therapy to 
standard cytotoxic gemcitabine therapy in pancreatic cancer.3 
It was a randomized, placebo-controlled, phase III trial 
comparing erlotinib with gemcitabine to gemcitabine alone 
in patients with locally advanced or metastatic pancreatic 
cancer. The study was powered to detect a 33% difference 
in OS and 569 patients were enrolled. The first 521 patients 
were randomized to erlotinib 100 mg per day or placebo; 
the remainder received erlotinib 150 mg per day or placebo. 
The study was reported using the log rank adjusted for 
performance status and extent of disease. Although the 
difference in median OS between the erlotinib and placebo 
groups was modest (6.24 months vs 5.91 months), there 
was a significant decrement in the hazard ratio for death 
(0.82; 95% CI, 0.69–0.99; P = 0.04) and a significant improve-
ment in 1-year survival rate (23% vs 17%, P = 0.02). In this trial, 
72% of the 282 erlotinib treated patients developed a rash.3
An additional small, phase II trial has demonstrated 
promising activity from the addition of erlotinib to cytotoxic 
chemotherapy in the second line. The combination of  erlotinib 
(150 mg daily) and capecitabine (1000 mg/m2, twice daily for 
14 days, every 3 weeks) was examined in 30 patients with 
gemcitabine-refractory, metastatic disease. A 10% overall 
response rate by RECIST criteria was seen. The median 
survival duration was 6.5 months, similar to results of other 
published phase II trials of second line therapy.22
Based on the NCIC CTG trial results, the Food and Drug 
Administration (FDA) and the European Medicines Evaluation 
Agency (EMEA) have approved the combination of erlo-
tinib and gemcitabine for first-line treatment of advanced 
pancreatic cancer. An informal, post hoc analysis performed 
in 2007 estimated the incremental cost-effectiveness ratio for 
the addition of erlotinib at US$410,000 per year of life saved. 
When adjusted for the quality-of-life impact of diarrhea, 
this number rose to US$430,000 to US$510,000 per quality 
adjusted life year.23 This has brought into question the clinical 
significance of erlotinib’s small survival benefit. A consensus 
has not yet been reached on the addition of erlotinib in the 
treatment of unselected patients with advanced disease.
The combination of gefitinib and gemcitabine has also 
been studied in a small, single-arm, phase II study in Europe, 
by the Hellenic Cooperative Oncology Group. Fifty-three 
patients with inoperable or metastatic pancreatic cancer 
were treated with gefitinib (250 mg per day) and gemcitabine 
(1000 mg/m2, weekly for 7 weeks, followed by a 1 week 
rest, then 1000 mg/m2 weekly for 3 of every 4 weeks). The 
6 month progression-free survival (PFS) was 30%, with a 
median PFS of 4.1 months. The 1-year survival rate was 27%, 
with a median survival of 7.3 months.24 These results are 
comparable to those from the erlotinib and gemcitabine 
arm in the NCIC CTG trial, but have not been confirmed in 
a randomized trial.
EGFR-directed antibody therapy 
in advanced pancreatic cancer
EGFR-directed antibody therapy has also been investigated 
in pancreatic cancer. Cetuximab was first studied in combina-
tion with gemcitabine in a phase II study of chemotherapy-
naïve patients with advanced disease. Forty-one patients with 
EGFR immunostain-positive tumors (6 locally advanced, 
34 metastatic) were treated with cetuximab (initial dose 
400 mg/m2, followed by 250 mg/m2 weekly) and gemcitabine 
(1000 mg/m2, weekly for 7 weeks, followed by a 1 week rest, 
then 1000 mg/m2, weekly for 3 weeks, every 4 weeks). Five 
patients (12.5%) achieved a partial response and 26 patients 
(63.4%) had stable disease. The median time to progression 
was 3.8 months, and the median OS duration was 7.1 months. 
The 1-year survival rate of 31.7% compared favorably to 
18% with gemcitabine alone in historical series. The combi-
nation was well tolerated with the most commonly reported 
toxicities of all grades as follows: rash (87.8%), nausea 
(61.0%), weight loss (58.5%), and diarrhea (53.7%).25
Subsequent to these seemingly promising results, two 
randomized trials have been presented that demonstrated no 
significant survival benefit from the addition of cetuximab to 
cytotoxic chemotherapy for advanced disease. The Southwest 
Oncology Group (SWOG) S0205 study was a randomized 
phase III trial of gemcitabine with or without cetuximab 
in patients with locally advanced or metastatic pancreatic 
adenocarcinoma in 766 patients. The data, presented in 
2007, demonstrated a nonsignificant difference in PFS; 
3 vs 3.5 months (P = 0.14), and OS duration; 6 vs 6.5 months 
(P = 0.058), in the gemcitabine alone vs gemcitabine and 
cetuximab groups, respectively.26 It should be noted that 
although these results were not statistically significant in this 
trial, numerically they are similar to the results in the control 
and experimental arms of the NCIC CTG trial of gemcitabine 
with or without erlotinib.
The second study was a randomized phase II trial 
conducted by the Eastern Cooperative Oncology Group 
(ECOG), which randomized 87 eligible patients with meta-
static pancreatic cancer to the Murren regimen of docetaxel 
and irinotecan with or without cetuximab.27,28 Updated 
results were presented in 2008. The study was not powered 
for comparison of the two arms, and all comparisons 
are exploratory. Unexpectedly, the patients treated with Biologics: Targets & Therapy 2009:3 422
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cetuximab had a shorter median survival duration of 
5.3 months compared to 6.5 months for the placebo group. 
A very short post-progression survival was observed in the 
cetuximab arm, not well explained by the data. Possible 
explanations include low utilization of second line chemo-
therapy, related either to the poor performance status of the 
patients at time of progression, or to persistent toxicities 
from the regimen, or an acceleration of tumor growth after 
withdrawal of cetuximab. The toxicity of this regimen 
was high, even without cetuximab. Grade 3 or 4 diarrhea 
was observed in 47% of patients in the three drug arm and 
the rate of treatment-related death was 4%.29
EGFR- and VEGF-targeted therapy 
combinations in advanced disease
Following up on the NCIC CTG trial of erlotinib and 
gemcitabine, Van Cutsem and colleagues evaluated the 
benefit of this regimen combined with the vascular endo-
thelial growth factor inhibitor, bevacizumab. In their trial, 
607 chemotherapy-naïve patients with metastatic disease 
were randomized to receive placebo or bevacizumab 
(5 mg/kg every 2 weeks) in combination with gemcitabine 
(1000 mg/m2, weekly for 7 weeks, followed by a 1 week 
rest, then 1000 mg/m2 weekly for 3 weeks, every 4 weeks) 
and erlotinib (100 mg/m2 daily). At the final analysis, 
454 patients had died (233 in the placebo arm; 221 in the 
bevacizumab arm). The median OS was not significantly 
different between the two groups (6.0 months for the placebo 
arm vs 7.1 months in the bevacizumab arm [HR 0.89; 95% 
CI 0.74–1.07]); however the median PFS was significantly 
longer for the bevacizumab-treated patients (3.6 months for 
the placebo arm vs. 4.6 months for the bevacizumab arm 
[HR 0.73; 95% CI 0.61–0.86; P  0.01]).30 The lack of 
statistical significance of the OS benefit may be due to the 
low power of this study.
Additional phase II trials have examined the combination 
of EGFR- and VEGF-targeted therapy in advanced pancreatic 
cancer. A multicenter, phase II trial was conducted that 
randomized 139 evaluable patients with advanced disease to 
receive either weekly cetuximab at standard doses or erlotinib 
(150 mg/m2 d1–5, 8–12, and 15–26 of a 28-day cycle) in 
addition to gemcitabine and bevacizumab. There were no 
Table 1 Summary of studies of eGFr targeted therapies for advanced pancreatic cancer
Study treatment Phase Pts Med OS  
(mos)
Med PFS 
(mos)
Rash 
[Gr3–4] (%)
EGFR targeted therapy
Moore 20073
  Gemcitabine + Placebo
  Gemcitabine + erlotinib
iii
284
285
5.91
6.24
3.55
3.75
29 [1]
72 [6]
Fountzilas 200824
  Gemcitabine + Gefitinib
ii
53 7.3 4.1 56 [4]
Xiong 200425
  Gemcitabine + Cetuximab
ii
41 7.1 3.8 88 [12]
Philip 200726
  Gemcitabine
  Gemcitabine + Cetuximab
iii
369
366
6
6.5
3
3.5
Nr [0]
Nr [7.1]
Burtness 200728
  irinotecan, Docetaxel
  irinotecan, Docetaxel + Cetuximab
ii
46
45
6.5
5.3
3.9
4.5
9 [0]
67 [0]
Combined EGFR and VEGF targeted therapy
van Cutsem 200930
  Gemcitabine, erlotinib + Placebo
  Gemcitabine, erlotinib + Bevacizumab
iii
301
306
6
7.1
3.6
4.6
44 [3]
49 [8]
Kindler 200831
  Gemcitabine, Bevacizumab + Cetuximab
  Gemcitabine, Bevacizumab + erlotinib
ii
68
71
7.8
7.2
5.0
5.1
Nr [10]
Nr [6]
Ko 200932
  Bevacizumab, Cetuximab
  Bevacizumab, Cetuximab + Gemcitabine
ii   
29 
28
 
Nr 
Nr
 
1.8 
3.5
 
58.6 [Nr] 
28.6 [Nr]
Abbreviations: eGFr, epidermal growth factor receptor; Gr, grade; mos, months; Nr, not reported; OS, overall survival; PFS, progression-free survival;   veGF,  vascular 
endothelial growth factor.Biologics: Targets & Therapy 2009:3 423
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statistically significant differences between the two groups in 
median OS (7.8 months vs 7.1 months for the cetuximab and 
erlotinib groups, respectively), both of which were superior 
to historical controls of gemcitabine monotherapy.31
Finally, an open-label, phase II, randomized trial examined 
the benefit of cetuximab and bevacizumab (10 mg/kg 
every 2 weeks) either alone or in combination with weekly 
gemcitabine. A total of 57 chemotherapy-naïve patients 
with advanced disease were randomized between the two 
groups. The combination of the two antibodies alone resulted 
in no objective responses and a median PFS of 1.8 months 
compared to 3.5 months with the addition of gemcitabine.32 
It seems that the use of the two antibodies alone is inferior 
to gemcitabine-based therapy.
EGFR-directed therapy 
in combination with radiation 
for locally advanced disease
The role of EGFR-directed therapy in combination with 
radiation therapy is under active investigation. Preclinical 
data have demonstrated that the addition of cetuximab or 
erlotinib to the combination of gemcitabine and radiation 
inhibits pancreatic cell growth significantly more than 
gemcitabine and radiation alone.12 A Phase 1 trial examined 
the combination of weekly gemcitabine (300 mg/m2), 
cetuximab (400 mg/m2 loading dose, then 250 mg/m2), 
and escalating doses of radiation in 25 patients with 
locally advanced disease. The combined therapy was well 
tolerated with no grade 4 toxicity reported and a maximum 
tolerated dose was not reached. Typical skin rash was 
observed in 19 patients (76%). Of the 20 evaluable patients, 
one demonstrated radiological complete response, 8 partial 
responses, and 6 patients had stable disease.33
Final results of a phase II trial examining the addition 
of cetuximab to gemcitabine and intensity modulated 
radiotherapy (IMRT) in patients with locally advanced, 
inoperable pancreatic cancer were recently presented.34 
Sixty-eight chemotherapy-naïve patients received IMRT 
with weekly gemcitabine (300 mg/m2) and cetuximab 
(400 mg/m2 loading dose, then 250 mg/m2). Patients were 
randomized following completion of radiotherapy to weekly 
gemcitabine alone (1000 mg/m2) for 4 weeks, or weekly 
gemcitabine (1000 mg/m2) and cetuximab (250 mg/m2) 
over 12 weeks. All patients were subsequently treated with 
weekly gemcitabine alone. One patient had a complete 
response, 23 had partial responses, 41 had stable disease, 
and only 3 had progressive disease. Fourteen patients went 
on to have complete surgical resections. For all patients, the 
1- and 2-year OS were 61% and 20%, respectively, with 
no significant differences between the two study groups. 
Median survival was 15 months. For comparison, in the 
recently presented ECOG trial, E4201, patients with locally 
advanced disease who received gemcitabine and IMRT had 
1- and 2-year OS of 50% and 12%, respectively. Median 
survival in E4201 was 11 months.35 Although these results 
appear promising, a randomized trial comparing cetuximab, 
gemcitabine, and radiation to gemcitabine and radiation has 
yet to be performed, and may not be justified in view of the 
negative trials in the metastatic setting.
Rash as a marker of efficacy
In multiple trials of EGFR-targeted therapies, a higher grade 
of rash has correlated with improved outcome. In the NCIC 
CTG trial of gemcitabine with or without erlotinib, median 
survival was significantly longer for the erlotinib-treated 
patients with grade 2 or greater rash compared to those with 
grade 1 or 0 (10.5 months, 5.8 months, and 5.3 months, 
respectively [P = 0.037]). This may be explained, in part, 
by the association of skin rash in this trial with age younger 
than 65 years (P = 0.01) and good performance status 
(P = 0.03).3
As in the NCIC CTG trial, a relationship between 
treatment efficacy and rash was suggested in the trial by 
Vervenne and colleagues of gemcitabine and erlotinib with 
bevacizumab or placebo. In the placebo arm, the 77 patients 
who experienced a grade 2 or higher rash had a median OS 
of 8.3 months compared to 4.3 months for the 123 patients 
who did not develop a rash. Results were similar in the beva-
cizumab arm (8.4 months vs 5.0 months). Neither difference 
met statistical significance.36
A similar association was demonstrated for cetuximab 
in the phase II trial of its combination with gemcitabine. 
The median OS in patients correlated with grade of rash 
as follows: 2.3 months for no rash, 5.7 months for grade 1, 
8.3 months for grade 2, and 13.9 months for grade 3. 
This association between rash grade and median OS was 
statistically significant (P  0.01).25
The etiology and clinical significance of this association 
remain to be determined. Rash may serve as a marker of 
host immunocompetency in that it signifies an ability to 
mount an inflammatory response. Alternatively, it has been 
postulated that variability in drug absorption or metabolism 
may be responsible; those patients who obtain a higher 
or more sustained blood level of drug being more likely 
to inhibit dermal EGFR and develop a rash. In support, Biologics: Targets & Therapy 2009:3 424
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gefitinib trough levels have been found to be highly 
variable amongst patients in clinical trials.37 Furthermore, 
higher trough levels of erlotinib have been associated 
with the severity of rash in patients treated for NSCLC.38 
Genetic polymorphisms in the ABCG2 transporter protein, 
which is involved in intestinal absorption and hepatic 
elimination of gefitinib and erlotinib, have been found to 
contribute to inter-patient differences in bioavailability and 
pharmacokinetics.38,39 Additionally, genetic differences in 
the cytochromes involved in their hepatic metabolism, such 
as CYP3A4/5, are partly responsible.18,37
The association between drug levels and rash has not 
been demonstrated, however, for the monoclonal antibodies, 
although in diseases in which cetuximab significantly 
delays progression or death, skin rash is also a positive 
predictive marker. A phase 1 escalating-dose trial of weekly 
cetuximab given to patients with epithelial malignancies 
found no association between cetuximab trough levels and 
the development of rash. Cetuximab at doses greater than 
250 mg/m2 did, however, lead to a dose-dependent decrease 
in EGFR protein expression levels in skin over time.40 
Additionally, a trial of dose escalation in patients who did 
not develop significant rash to cetuximab at standard doses 
was performed. Patients who had less than a grade 2 rash at 
standard doses of cetuximab (250 mg/m2) were randomized 
to receive either standard dose cetuximab or escalating doses 
until a grade 2 or higher rash developed or the maximum 
dose of 500 mg/m2 was reached. Contrary to the hypothesis, 
there was no difference in rash incidence between the two 
groups.41
An alternative explanation for the association between 
rash and efficacy of EGFR targeted therapy may involve 
genetic variability affecting the expression of EGFR in both 
germline and tumor cells. A genetic polymorphism in EGFR 
expression involving a dinucleotide repeat polymorphism 
in EGFR intron 1 has been described. This CA repeat is 
located upstream to an EGFR enhancer region and in vitro 
data have shown an inverse correlation between the number 
of CA repeats and EGFR transcription.42 This polymor-
phism was prospectively associated with the development 
of rash from gefitinib therapy in patients with lung cancer.43 
Whether this polymorphism correlates with response to 
EGFR TKI therapy in pancreatic cancer is unknown.
Limitations of EGFR-targeted therapy
Although EGFR is a frequently expressed target that plays an 
active role in pancreatic adenocarcinoma carcinogenesis, the 
efficacy of EGFR targeted therapy has not met expectations. 
There are several proposed mechanisms that relate to both 
limitations of the agents tested to date and to the biological 
environment of pancreatic cancer.
First, monoclonal antibodies, such as cetuximab and 
panitumimab, are large molecules that may not distribute 
well to or within pancreatic tumors. Optimal dosing for 
these agents may not be known and may dependent on 
EGFR content, ligand levels, or other not yet identified 
variables. As mentioned above, the development of rash 
is associated with treatment efficacy of these agents and 
correlates with trough levels of the EGFR TKIs, suggesting 
that pharmacogenetic differences in absorption and metabo-
lism may lead to subtherapeutic blood levels in a proportion 
of patients.
Furthermore, EGFR TKIs have not resulted in any 
sustained tumor responses in pancreatic cancer trials, as they 
have in a proportion of patients with NSCLC. This is likely 
due to differences in the prevalence of activating mutations 
in EGFR that have been associated with these prolonged 
responses in NSCLC.44 In four small case series, activating 
EGFR gene mutations were identified in only 2 out of 
170 (1.2%) specimens of pancreatic cancer.45–48
Mechanisms of resistance 
to EGFR targeted therapy
Above all, a high rate of acquired or inherent resistance of 
pancreatic cancer to EGFR targeted therapy is most likely to 
explain the lack of efficacy. Multiple potential mechanisms 
of EGFR targeted therapy have been well described.49–51
The most well-defined mechanisms of resistance involve 
EGFR independent activation of downstream mediators. 
Activating mutations of KRAS, for example, have been 
examined retrospectively in several clinical trials and 
have been associated with a lack of response to or survival 
benefit from EGFR-targeted antibodies in colorectal cancer, 
as well as a lack of response to EGFR TKI’s in NSCLC.52–54 
In pancreatic cancer, KRAS mutations are prevalent, 
found in 50 to 95% of tumor samples in multiple series.5,6 
The relationship with KRAS mutations and efficacy of 
EGF-targeted therapies in this disease has yet to be estab-
lished, but can be inferred as a likely mechanism of resistance 
for a large proportion of patients.
Another example of resistance due to constitutive 
activation of a downstream mediator involves PI3K-Akt. 
Gefitinib-resistant cell lines of squamous cell cancer devel-
oped in cell culture maintain activity of PI3K-Akt despite 
demonstrable inhibition of EGFR. The increased PI3K-Akt 
activity in these cells is due to increased activity of an Biologics: Targets & Therapy 2009:3 425
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alternative pathway, the insulin-like growth factor 1 receptor 
(IGF1R) pathway. Down-regulation of the insulin-like 
growth factor binding protein has been implemented in this 
process. Combined inhibition of both EGFR and IGF1R with 
both gefitinib and a targeted anti-IGF1R TKI is effective in 
inhibiting both PI3K-Akt activity and cell growth in cell lines. 
This has been verified in animal models, as well. In mice 
bearing xenografts of squamous cell carcinoma, treatment 
with gefitinib alone led to reduction in tumor size, though 
most tumors ultimately progressed on this therapy. Treatment 
with an anti-IGF1R monoclonal antibody alone led only to 
minor and short-lived partial responses. Combined therapy 
with both gefinitib and the anti-IGF1R antibody, however, led 
to complete responses in all of the treated mice that persisted 
for several months after the discontinuation of therapy.55
In light of these promising preclinical data, the Southwest 
Oncology Group has begun enrolling patients to a combina-
tion phase I/randomized phase II trial comparing gemcitabine 
and erlotinib therapy with or without the addition of an 
IGF1R antibody, IMC-A12, in chemo-naïve patients with 
metastatic pancreatic cancer. Study completion in 2011 is 
anticipated.
An alternative mechanism of EGFR resistance via 
increased PI3K-Akt activity involves PTEN, a lipid phos-
phatase and tumor suppressor protein. Loss of PTEN (often 
through loss of one allele and mutation in the other) leads 
to accumulation of its major substrate, phosphatidylinositol 
3,4,5-triphosphate, which binds and activates Akt.56,57 
PTEN loss has been associated with resistance to cetuximab 
therapy in a small study of 27 patients with metastatic colon 
cancer.58 PTEN mutations also result in gefitinib resistance 
in breast cancer cells lines. Gefinitib therapy was associ-
ated with upregulation of PI3k-Akt in these PTEN mutant 
cells. Furthermore, restoration of wild type PTEN via an 
adenoviral vector led to decreased activity of the PI3K-Akt 
pathway and improved response of these cells to gefitinib 
supporting unopposed PI3K-Akt activity as the mechanism 
of resistance.59
In NSCLC, EGFR TKI resistance has also been 
attributed to persistent activity of PI3K-Akt, but through 
yet another mechanism. Amplification of MET, a proto-
oncogene that encodes a transmembrane tyrosine kinase 
receptor for the hepatocyte growth factor (scatter factor) 
has been described as a mechanism of acquired resistance 
to gefitinib in NSCLC cell lines. MET amplification leads 
to EGFR-independent activation of PI3K-Akt through 
activation of erbB-3-dependent signaling. MET targeted 
therapy alone is ineffective at overcoming this resistance, 
but in combination with gefitinib tumor cell death has been 
achieved. Furthermore, examination of tumor samples from 
patients who have developed resistance to EGFR TKI therapy 
has shown emergence of MET gene amplification that was 
not present in tumor samples prior to the initiation of the 
treatment.60
Therapies that directly inhibit P13K-Akt have been 
developed, as well. In mice bearing gefinitib-resistant 
NSCLC xenografts, the PI3K inhibitor PX-866 was shown 
to enhance the anti-tumor effect of gefitinib. Tumor growth, 
however, slowly increased towards the end of the treatment 
period, suggesting emergence of yet additional resistance 
pathways. The major toxicity of this agent was reversible 
hyperglycemia that resulted from a target-related decrease 
in insulin sensitivity.61
Additionally, efforts to restore sensitivity to anti-EGFR 
resistant tumor cells have focused on targeting a downstream 
mediator of the PI3K-Akt pathway: the mammalian target 
of rapamycin (mTOR). mTOR is a serine/threonine-specific 
kinase responsible for mitogen-induced cell proliferation 
and survival signaling.62,63 mTOR is thought to integrate 
proliferative, antiapoptotic, and antiogenic signaling by 
connecting VEGF, hypoxia-inducible factor 1 (HIF-1) 
and multiple ErbB family receptor pathways. The mTOR 
inhibitor, everolimus, has been studied in combination with 
EGFR targeted therapies in a variety of resistant tumor cell 
lines. In combination with cetuximab or gefitinib, everolimus 
resulted in strong reduction of PI3K-Akt activity. It also 
restored anti-EGFR therapy growth inhibition of resistant 
cell lines in a dose-dependent fashion. Of particular interest, 
gefitinib efficacy was restored when given with everolimus to 
resistant prostate cancer cells harboring an inactivating PTEN 
mutation.64 Phase one clinical trials of therapies targeting 
both mTOR and EGFR, such as everolimus and cetuximab, 
are currently enrolling patients.
Finally, resistance to TKI therapy can develop through 
conformational alterations in the ATP binding domain of 
the EGFR. As previously described, known mutations in 
the EGFR gene result in increased activity of the receptor 
and are associated with an improved response to EGFR TKI 
therapy. Contrarily, a point mutation in the EGFR gene, 
which results in the substitution of methionine for threonine 
at position 790 (T790M), decreases the ability of erlotinib or 
gefitinib to inhibit EGFR. These mutations have been identi-
fied in approximately 50% of lung adenocarcinoma samples 
from patients who had acquired resistance to EGFR TKI 
therapy.65–67 The mutation is thought to result in resistance 
by altering the structure of the ATP-binding pocket in the Biologics: Targets & Therapy 2009:3 426
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tyrosine kinase domain. This alteration leads to increased 
affinity for ATP, which can then out-compete gefitinib and/or 
erlotinib for binding to the receptor. Irreversible inhibitors 
of EGFR tyrosine kinase are currently in development that 
form permanent covalent bonds to the binding domain rather 
than having to compete with ATP for temporary interactions. 
They have been shown to successfully inhibit EGFR bearing 
the T790M mutation in vitro.50
Conclusions
Erlotinib is the only EGFR-targeted therapy currently approved 
by the FDA for use (in combination with gemcitabine) in the 
management of advanced pancreatic cancer. The clinical 
significance of its additional benefit has been appropriately 
questioned.23 The identification of biological factors that 
predict benefit is needed to improve patient selection and 
thereby the utility of these drugs. Similarly, prospective 
research is warranted to determine whether the development 
of rash should act as a correlate for their efficacy.
Pancreatic cancer appears to have high rates of resistance 
to EGFR-targeted therapies through several mechanisms 
that include receptor-independent activation of downstream 
mediators. Our ability to overcome resistance mechanisms 
will ultimately determine the success of EGFR-targeted 
therapies in this malignancy. Several approaches have had 
success in preclinical models. We await the results of their 
application in clinical trials.
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